DK1015596T3 - Fusionsproteiner omfattende HIV-1 Tat- og/eller Nef-proteiner - Google Patents

Fusionsproteiner omfattende HIV-1 Tat- og/eller Nef-proteiner

Info

Publication number
DK1015596T3
DK1015596T3 DK98952625T DK98952625T DK1015596T3 DK 1015596 T3 DK1015596 T3 DK 1015596T3 DK 98952625 T DK98952625 T DK 98952625T DK 98952625 T DK98952625 T DK 98952625T DK 1015596 T3 DK1015596 T3 DK 1015596T3
Authority
DK
Denmark
Prior art keywords
proteins
tat
hiv
nef
fusion proteins
Prior art date
Application number
DK98952625T
Other languages
English (en)
Other versions
DK1015596T4 (da
Inventor
Claudine Bruck
Stephane Andre Georges Godart
Martine Marchand
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10819735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1015596(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of DK1015596T3 publication Critical patent/DK1015596T3/da
Publication of DK1015596T4 publication Critical patent/DK1015596T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK98952625.6T 1997-09-26 1998-09-17 Fusionsproteiner omfattende HIV-1 Tat- og/eller Nef-proteiner DK1015596T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9720585.0A GB9720585D0 (en) 1997-09-26 1997-09-26 Vaccine
PCT/EP1998/006040 WO1999016884A1 (en) 1997-09-26 1998-09-17 Fusion proteins comprising hiv-1 tat and/or nef proteins

Publications (2)

Publication Number Publication Date
DK1015596T3 true DK1015596T3 (da) 2007-01-02
DK1015596T4 DK1015596T4 (da) 2010-07-12

Family

ID=10819735

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98952625.6T DK1015596T4 (da) 1997-09-26 1998-09-17 Fusionsproteiner omfattende HIV-1 Tat- og/eller Nef-proteiner

Country Status (27)

Country Link
EP (1) EP1015596B2 (da)
JP (2) JP2001518300A (da)
KR (1) KR100554487B1 (da)
CN (1) CN1188519C (da)
AR (2) AR017147A1 (da)
AT (1) ATE338128T1 (da)
AU (1) AU746564B2 (da)
BR (1) BR9812547A (da)
CA (1) CA2305013C (da)
CO (1) CO4810339A1 (da)
CZ (1) CZ302878B6 (da)
DE (1) DE69835756T3 (da)
DK (1) DK1015596T4 (da)
ES (1) ES2272012T5 (da)
GB (1) GB9720585D0 (da)
HU (1) HUP0004896A3 (da)
IL (1) IL135102A0 (da)
NO (2) NO328824B1 (da)
NZ (1) NZ503482A (da)
PL (1) PL195243B1 (da)
PT (1) PT1015596E (da)
SA (1) SA98190877B1 (da)
SI (1) SI1015596T2 (da)
TR (1) TR200000864T2 (da)
TW (1) TW499436B (da)
WO (1) WO1999016884A1 (da)
ZA (1) ZA988789B (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
GB9820525D0 (en) * 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
EP1156825A2 (en) * 1999-02-25 2001-11-28 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogens comprising a peptide and a carrier derived from h.influenzae protein d
EP1175436B1 (en) * 1999-04-12 2006-10-11 Heart Biosystems GmbH Transiently immortalized cells for use in gene therapy
DE60023300T2 (de) * 1999-06-29 2006-07-06 Glaxosmithkline Biologicals S.A. Verwendung von cpg als adjuvans für hivimpstoff
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
WO2001054719A2 (en) * 2000-01-31 2001-08-02 Smithkline Beecham Biologicals S.A. Vaccine for the prophylactic or therapeutic immunization against hiv
US6472176B2 (en) 2000-12-14 2002-10-29 Genvec, Inc. Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
EP1279404A1 (en) * 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
EP1453543B1 (en) 2001-11-21 2017-08-30 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
KR100466382B1 (ko) * 2002-01-08 2005-01-14 주식회사 엘지생명과학 인간 면역 결핍 바이러스-1, -2 타입의 단백질이 융합된 재조합 콤보 단백질, 이의 생산방법, 이를 포함하는 벡터, 형질전환된 대장균 및 진단키트
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
CA2483640A1 (en) 2002-05-16 2003-11-27 Bavarian Nordic A/S Fusion protein of hiv regulatory/accessory proteins
GB0225788D0 (en) 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US7927580B2 (en) 2004-03-16 2011-04-19 Nanirx, Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0507003D0 (en) * 2005-04-06 2005-05-11 Molmed Spa Therapeutic
KR101441843B1 (ko) * 2005-10-18 2014-09-17 내셔날 쥬이쉬 헬스 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및 사용 방법
EP2463362B1 (en) 2007-11-28 2017-11-08 The Trustees Of The University Of Pennsylvania Simian subfamily c adenovirus SAdv-31 and uses thereof
MX2010005858A (es) 2007-11-28 2010-06-11 Univ Pennsylvania Adenovirus e simianos sadv-39, sadv-25.2, sadv-26, sadv-30, sadv-37 y sadv-38.
CA2716928C (en) 2008-03-04 2018-04-10 The Trustees Of The University Of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
EP2285832B1 (en) 2008-05-16 2020-08-26 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
ES2525411T3 (es) 2008-07-21 2014-12-22 Taiga Biotechnologies, Inc. Células anucleadas diferenciadas y método para preparar las mismas
EP2318435B1 (en) 2008-08-28 2015-12-23 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
US8940290B2 (en) 2008-10-31 2015-01-27 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50 and uses thereof
NZ595060A (en) 2009-03-23 2013-05-31 Pin Pharma Inc Treatment of cancer with immunostimulatory hiv tat derivative polypeptides
CN102575232B (zh) 2009-05-29 2015-07-22 宾夕法尼亚大学托管会 猿腺病毒41及其应用
WO2012071318A2 (en) 2010-11-23 2012-05-31 The Trustees Of The University Of Pennsylvania Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof
JP5968343B2 (ja) * 2011-03-15 2016-08-10 インダストリー−アカデミック コーポレーション ファウンデーション，ヨンセイ ユニバーシティ バイオピン
WO2013173702A2 (en) 2012-05-18 2013-11-21 The Trustees Of The University Of Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
WO2014012090A1 (en) 2012-07-13 2014-01-16 The Broad Institute, Inc. Molecular sleds comprising a positively-charged amino acid sequence and a molecular cargo and uses thereof
JP6285930B2 (ja) 2012-07-20 2018-02-28 タイガ バイオテクノロジーズ，インク． 造血コンパートメントの再構築及び自家再構築の増進
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
JP2016533352A (ja) 2013-10-04 2016-10-27 ピーアイエヌ ファーマ インコーポレイテッド 免疫刺激性ＨＩＶ Ｔａｔ誘導体ポリペプチドによる癌の治療
PE20170261A1 (es) 2014-05-13 2017-04-12 Univ Pennsylvania Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos
JP6886406B2 (ja) * 2015-04-16 2021-06-16 ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク コバルトポルフィリン・リン脂質コンジュゲート及びポリヒスチジンタグを含むナノ構造体
US11207421B2 (en) 2015-04-16 2021-12-28 The Research Foundation For The State University Of New York Nanostructures comprising cobalt porphyrin-phospholipid conjugates and polyhistidine-tags
KR20190092472A (ko) 2016-12-02 2019-08-07 타이가 바이오테크놀로지스, 인코포레이티드 나노입자 제제
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
WO2020210231A1 (en) 2019-04-08 2020-10-15 Taiga Biotechnologies, Inc. Compositions and methods for the cry opreservation of immune cells
EP3969041A4 (en) 2019-05-14 2023-05-10 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION
CN117881786A (zh) 2021-04-27 2024-04-12 世代生物公司 表达治疗性抗体的非病毒dna载体及其用途
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9003010D0 (en) * 1990-02-09 1990-04-04 Glaxo Group Ltd Gene expression in yeast cells
WO1993007897A1 (en) * 1991-10-21 1993-04-29 Medimmune, Inc. Bacterial expression vectors containing dna encoding secretion signals of lipoproteins
CA2135642C (en) * 1992-08-21 1999-12-14 James G. Barsoum Tat-derived transport polypeptides
AU675702B2 (en) * 1993-01-26 1997-02-13 Leslie R. Coney Compositions and methods for delivery of genetic material
PL322143A1 (en) * 1995-03-08 1998-01-05 Neovacs Non-topxic immunogenes originating frommretroviral regulator protein, antibodies as such, method of preparing them and pharmaceutic compositions containing them
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine

Also Published As

Publication number Publication date
HUP0004896A3 (en) 2003-05-28
IL135102A0 (en) 2001-05-20
DE69835756T2 (de) 2007-09-13
HUP0004896A1 (hu) 2001-04-28
KR20010024287A (ko) 2001-03-26
WO1999016884A1 (en) 1999-04-08
DK1015596T4 (da) 2010-07-12
CN1188519C (zh) 2005-02-09
CA2305013A1 (en) 1999-04-08
NO20001508D0 (no) 2000-03-23
PT1015596E (pt) 2006-12-29
GB9720585D0 (en) 1997-11-26
AR080331A2 (es) 2012-03-28
DE69835756D1 (de) 2006-10-12
AU1025599A (en) 1999-04-23
AR017147A1 (es) 2001-08-22
ZA988789B (en) 2000-03-29
EP1015596B2 (en) 2010-04-14
ES2272012T3 (es) 2007-04-16
NO20076467L (no) 2000-05-18
CN1279718A (zh) 2001-01-10
JP2001518300A (ja) 2001-10-16
NZ503482A (en) 2001-09-28
AU746564B2 (en) 2002-05-02
ES2272012T5 (es) 2010-07-06
ATE338128T1 (de) 2006-09-15
NO20001508L (no) 2000-05-18
EP1015596B1 (en) 2006-08-30
CZ302878B6 (cs) 2012-01-04
PL195243B1 (pl) 2007-08-31
PL339432A1 (en) 2000-12-18
NO328824B1 (no) 2010-05-25
TW499436B (en) 2002-08-21
CA2305013C (en) 2008-04-08
HK1030431A1 (en) 2001-05-04
SA98190877B1 (ar) 2006-09-10
DE69835756T3 (de) 2010-09-30
CZ20001091A3 (cs) 2000-09-13
JP2009213492A (ja) 2009-09-24
KR100554487B1 (ko) 2006-03-03
CO4810339A1 (es) 1999-06-30
SI1015596T2 (sl) 2010-07-30
SI1015596T1 (sl) 2007-02-28
EP1015596A1 (en) 2000-07-05
TR200000864T2 (tr) 2000-08-21
BR9812547A (pt) 2000-07-25

Similar Documents

Publication Publication Date Title
DK1015596T4 (da) Fusionsproteiner omfattende HIV-1 Tat- og/eller Nef-proteiner
NO983364L (no) Konsensusproteiner
DE69804857D1 (de) Integritätsprüfung von elektroden
IS4814A (is) Tilbúin HIV gen
DE69831486D1 (de) Antiproliferative zubereitungen
FI952900A7 (fi) Polypeptidi ja siitä valmistettu anti-HIV-aine
DE69814367D1 (de) Filmueberzogene tabletten von oxacarbazepin
TR199801301A3 (tr) Insan semaforin L(H-sema-L) ve diger türlerdeki mütekabil semaforinler.
NO882917L (no) Fusjonsproteiner og partikler.
DE69705628D1 (de) Chlorfluorkohlenwasserstoff freie aerosol-arzneizubereitungen enthaltend mometasonfuroat
DE69019572D1 (de) Gasauflösung.
NO980566D0 (no) Allergen-XCD32 fusjonsproteiner
EE200200353A (et) Inimese heparanaasisarnane polüpeptiid ja nukleiinhape
EP0679051A3 (de) Kontaktierung von Betätigungs- und Anzeigemitteln.
NO993354D0 (no) Voksholdige preparater
AU2002300390A1 (en) Fusion proteins comprising HIV-1 TAT and/or NEF proteins
FI955537A7 (fi) Fibrinolyyttiset ja hyytymistä estävät proteiinit
FI972328A0 (fi) Foerflyttningsanordning foer flata foeremaol i en bunt
DE69502429D1 (de) Auflösung von Gas
FI972573A0 (fi) Trimningsmaskin foer en vaevnad saosom en vira eller motsvarande i en pappersmaskin/kartongsmaskin
DE69830516D1 (de) Copolyester objekt
FI954611L (fi) Ig-CD4-fuusioproteiineja ja niiden käyttö HIV:n tai SIV:n havaitsemiseksi
SE9701041D0 (sv) Novel proteins and their use
DE59812220D1 (de) Halte- und trageband
BR7501788U (pt) Faca calçada por brasagem